CL2013002740A1 - Compuestos macrociclicos analogos de sangliferina, inhibidores de la ciclofilina; procedimiento de preparacion; intermediario; composicion farmaceutica; y uso en el tratamiento de infecciones virales tales como infeccion por vhc o vih, o uso como inmunosupresor o agente antiinflamatorio. - Google Patents
Compuestos macrociclicos analogos de sangliferina, inhibidores de la ciclofilina; procedimiento de preparacion; intermediario; composicion farmaceutica; y uso en el tratamiento de infecciones virales tales como infeccion por vhc o vih, o uso como inmunosupresor o agente antiinflamatorio.Info
- Publication number
- CL2013002740A1 CL2013002740A1 CL2013002740A CL2013002740A CL2013002740A1 CL 2013002740 A1 CL2013002740 A1 CL 2013002740A1 CL 2013002740 A CL2013002740 A CL 2013002740A CL 2013002740 A CL2013002740 A CL 2013002740A CL 2013002740 A1 CL2013002740 A1 CL 2013002740A1
- Authority
- CL
- Chile
- Prior art keywords
- hcv
- pharmaceutical composition
- hiv infection
- viral infections
- inflammatory agent
- Prior art date
Links
- 208000031886 HIV Infections Diseases 0.000 title abstract 2
- 208000037357 HIV infectious disease Diseases 0.000 title abstract 2
- 208000036142 Viral infection Diseases 0.000 title abstract 2
- 229940121363 anti-inflammatory agent Drugs 0.000 title abstract 2
- 239000002260 anti-inflammatory agent Substances 0.000 title abstract 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 title abstract 2
- 239000003018 immunosuppressive agent Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000134 cyclophilin inhibitor Substances 0.000 title 1
- 229960003444 immunosuppressant agent Drugs 0.000 title 1
- 230000001861 immunosuppressant effect Effects 0.000 title 1
- 150000002678 macrocyclic compounds Chemical class 0.000 title 1
- 230000009385 viral infection Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Transplantation (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1105293.3A GB201105293D0 (en) | 2011-03-29 | 2011-03-29 | Novel compounds and methods for their production |
| GBGB1113629.8A GB201113629D0 (en) | 2011-08-08 | 2011-08-08 | Novel compounds and methods for their production |
| GBGB1202060.8A GB201202060D0 (en) | 2012-02-07 | 2012-02-07 | Novel compounds and methods for their production |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013002740A1 true CL2013002740A1 (es) | 2014-07-11 |
Family
ID=46001313
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013002740A CL2013002740A1 (es) | 2011-03-29 | 2013-09-25 | Compuestos macrociclicos analogos de sangliferina, inhibidores de la ciclofilina; procedimiento de preparacion; intermediario; composicion farmaceutica; y uso en el tratamiento de infecciones virales tales como infeccion por vhc o vih, o uso como inmunosupresor o agente antiinflamatorio. |
| CL2013002739A CL2013002739A1 (es) | 2011-03-29 | 2013-09-25 | Compuesto macrociclicos analogo de sangliferina, inhibidor de la ciclofilina; forma cristalina solida y forma de polimorfo cristalino; procedimientos para prepararlos; intermediario; composicion farmaceutica; y uso en el tratamiento de infecciones virales tales como vhc o vih o uso como inmunosupresor o agente antiinflamatorio. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013002739A CL2013002739A1 (es) | 2011-03-29 | 2013-09-25 | Compuesto macrociclicos analogo de sangliferina, inhibidor de la ciclofilina; forma cristalina solida y forma de polimorfo cristalino; procedimientos para prepararlos; intermediario; composicion farmaceutica; y uso en el tratamiento de infecciones virales tales como vhc o vih o uso como inmunosupresor o agente antiinflamatorio. |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US9090657B2 (enExample) |
| EP (2) | EP2691413B1 (enExample) |
| JP (2) | JP6118793B2 (enExample) |
| KR (2) | KR101911484B1 (enExample) |
| CN (3) | CN103619869B (enExample) |
| AR (1) | AR085724A1 (enExample) |
| AU (2) | AU2012235880B2 (enExample) |
| BR (2) | BR112013024974A2 (enExample) |
| CA (2) | CA2830827C (enExample) |
| CL (2) | CL2013002740A1 (enExample) |
| CY (2) | CY1116318T1 (enExample) |
| DK (2) | DK2691412T3 (enExample) |
| EA (2) | EA023907B1 (enExample) |
| ES (2) | ES2533438T3 (enExample) |
| HR (2) | HRP20150184T1 (enExample) |
| IL (2) | IL228508B (enExample) |
| JO (1) | JO3063B1 (enExample) |
| MX (2) | MX345352B (enExample) |
| MY (2) | MY170637A (enExample) |
| PH (2) | PH12013502000B1 (enExample) |
| PL (2) | PL2691413T3 (enExample) |
| PT (2) | PT2691412E (enExample) |
| RS (2) | RS53964B1 (enExample) |
| SG (2) | SG193569A1 (enExample) |
| SI (2) | SI2691412T1 (enExample) |
| TW (1) | TWI525098B (enExample) |
| UY (1) | UY33993A (enExample) |
| WO (2) | WO2012131371A1 (enExample) |
| ZA (2) | ZA201307149B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2541853T3 (es) | 2010-02-09 | 2015-07-27 | Neurovive Pharmaceutical Ab | Compuestos basados en sangliferina |
| JO3063B1 (ar) * | 2011-03-29 | 2017-03-15 | Neurovive Pharmaceutical Ab | مركب مبتكر وطرق لانتاجه |
| CN103130734A (zh) * | 2011-12-01 | 2013-06-05 | 上海药明康德新药开发有限公司 | 一种合成1,2-吗啉盐酸盐的方法 |
| CN105695541B (zh) * | 2016-03-10 | 2019-03-15 | 苏州华赛生物工程技术有限公司 | 一种抗生素nvp018中间体的分离纯化方法 |
| KR20180036522A (ko) * | 2016-09-30 | 2018-04-09 | (주)나노믹스 | 스틸벤 유도체 및 그 제조 방법 |
| MX2019005349A (es) * | 2016-11-18 | 2019-08-05 | Neurovive Pharmaceutical Ab | Uso de analogos de sangliferina macrociclicos como compuestos anticancerigenos. |
| CN112410353B (zh) * | 2019-08-23 | 2023-01-24 | 上海医药工业研究院 | 一种fkbS基因、含其的基因工程菌及其制备方法和用途 |
| CN114786777A (zh) | 2019-11-04 | 2022-07-22 | 锐新医药公司 | Ras抑制剂 |
| EP4214209A1 (en) | 2020-09-15 | 2023-07-26 | Revolution Medicines, Inc. | Indole derivatives as ras inhibitors in the treatment of cancer |
| EP4334325A1 (en) | 2021-05-05 | 2024-03-13 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| CN115028681B (zh) * | 2022-08-11 | 2022-11-15 | 中国科学院微生物研究所 | 一种降解亲环素a的嵌合体化合物及其制备方法与应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR006514A1 (es) | 1995-07-04 | 1999-09-08 | Sandoz Ag | Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende |
| US6124453A (en) | 1995-07-04 | 2000-09-26 | Novartis Ag | Macrolides |
| WO2006138507A1 (en) * | 2005-06-17 | 2006-12-28 | Novartis Ag | Use of sanglifehrin in hcv |
| EP2124992A2 (en) | 2007-01-04 | 2009-12-02 | Debiopharm S.A. | Non-immunosuppressive cyclosporin for treatment of ullrich congenital muscular dystrophy |
| CN101691575B (zh) * | 2008-09-24 | 2013-06-05 | 中国科学院上海有机化学研究所 | 一种萨菲菌素的生物合成基因簇 |
| CN102224242B (zh) | 2008-09-24 | 2014-09-24 | 中国科学院上海有机化学研究所 | 新基因簇 |
| ES2541853T3 (es) | 2010-02-09 | 2015-07-27 | Neurovive Pharmaceutical Ab | Compuestos basados en sangliferina |
| WO2011098808A1 (en) * | 2010-02-09 | 2011-08-18 | Biotica Technology Limited | Sanglifehrin based compounds |
| WO2011098805A1 (en) | 2010-02-09 | 2011-08-18 | Biotica Technology Limited | Sanglifehrin based compounds |
| ES2703433T3 (es) * | 2010-12-20 | 2019-03-08 | Neurovive Pharmaceutical Ab | Derivados de sangliferina y métodos para su producción |
| JO3063B1 (ar) * | 2011-03-29 | 2017-03-15 | Neurovive Pharmaceutical Ab | مركب مبتكر وطرق لانتاجه |
-
2012
- 2012-03-12 JO JOP/2012/0053A patent/JO3063B1/ar active
- 2012-03-28 TW TW101110673A patent/TWI525098B/zh not_active IP Right Cessation
- 2012-03-28 AR ARP120101043A patent/AR085724A1/es unknown
- 2012-03-29 CA CA2830827A patent/CA2830827C/en not_active Expired - Fee Related
- 2012-03-29 PT PT127165389T patent/PT2691412E/pt unknown
- 2012-03-29 KR KR1020137028095A patent/KR101911484B1/ko not_active Expired - Fee Related
- 2012-03-29 SG SG2013070974A patent/SG193569A1/en unknown
- 2012-03-29 SG SG2013070966A patent/SG193568A1/en unknown
- 2012-03-29 EP EP12716539.7A patent/EP2691413B1/en active Active
- 2012-03-29 UY UY0001033993A patent/UY33993A/es not_active Application Discontinuation
- 2012-03-29 CN CN201280026190.3A patent/CN103619869B/zh not_active Expired - Fee Related
- 2012-03-29 PT PT127165397T patent/PT2691413E/pt unknown
- 2012-03-29 HR HRP20150184TT patent/HRP20150184T1/hr unknown
- 2012-03-29 CN CN201611126823.4A patent/CN107417766A/zh active Pending
- 2012-03-29 CN CN201280026793.3A patent/CN103635484B/zh active Active
- 2012-03-29 WO PCT/GB2012/050700 patent/WO2012131371A1/en not_active Ceased
- 2012-03-29 AU AU2012235880A patent/AU2012235880B2/en not_active Ceased
- 2012-03-29 KR KR1020137027773A patent/KR101868084B1/ko not_active Expired - Fee Related
- 2012-03-29 MX MX2013011051A patent/MX345352B/es active IP Right Grant
- 2012-03-29 PH PH1/2013/502000A patent/PH12013502000B1/en unknown
- 2012-03-29 MY MYPI2013701788A patent/MY170637A/en unknown
- 2012-03-29 EA EA201391396A patent/EA023907B1/ru not_active IP Right Cessation
- 2012-03-29 HR HRP20150187TT patent/HRP20150187T1/hr unknown
- 2012-03-29 BR BR112013024974A patent/BR112013024974A2/pt not_active Application Discontinuation
- 2012-03-29 CA CA2830831A patent/CA2830831C/en not_active Expired - Fee Related
- 2012-03-29 WO PCT/GB2012/050707 patent/WO2012131377A1/en not_active Ceased
- 2012-03-29 AU AU2012235961A patent/AU2012235961B2/en not_active Ceased
- 2012-03-29 BR BR112013024965A patent/BR112013024965A2/pt not_active Application Discontinuation
- 2012-03-29 DK DK12716538T patent/DK2691412T3/en active
- 2012-03-29 US US13/433,944 patent/US9090657B2/en active Active
- 2012-03-29 EP EP12716538.9A patent/EP2691412B1/en active Active
- 2012-03-29 ES ES12716539.7T patent/ES2533438T3/es active Active
- 2012-03-29 SI SI201230145T patent/SI2691412T1/sl unknown
- 2012-03-29 SI SI201230146T patent/SI2691413T1/sl unknown
- 2012-03-29 DK DK12716539T patent/DK2691413T3/en active
- 2012-03-29 PL PL12716539T patent/PL2691413T3/pl unknown
- 2012-03-29 MX MX2013011043A patent/MX345351B/es active IP Right Grant
- 2012-03-29 US US14/006,341 patent/US9139613B2/en active Active
- 2012-03-29 JP JP2014501720A patent/JP6118793B2/ja active Active
- 2012-03-29 PH PH1/2013/502016A patent/PH12013502016A1/en unknown
- 2012-03-29 JP JP2014501719A patent/JP6118792B2/ja not_active Expired - Fee Related
- 2012-03-29 RS RS20150162A patent/RS53964B1/sr unknown
- 2012-03-29 RS RS20150161A patent/RS53963B1/sr unknown
- 2012-03-29 MY MYPI2013701789A patent/MY170618A/en unknown
- 2012-03-29 PL PL12716538T patent/PL2691412T3/pl unknown
- 2012-03-29 EA EA201391399A patent/EA023848B1/ru not_active IP Right Cessation
- 2012-03-29 ES ES12716538.9T patent/ES2533437T3/es active Active
-
2013
- 2013-09-17 IL IL228508A patent/IL228508B/en active IP Right Grant
- 2013-09-17 IL IL228509A patent/IL228509B/en active IP Right Grant
- 2013-09-23 ZA ZA2013/07149A patent/ZA201307149B/en unknown
- 2013-09-25 CL CL2013002740A patent/CL2013002740A1/es unknown
- 2013-09-25 CL CL2013002739A patent/CL2013002739A1/es unknown
- 2013-09-26 ZA ZA2013/07231A patent/ZA201307231B/en unknown
-
2015
- 2015-02-27 CY CY20151100207T patent/CY1116318T1/el unknown
- 2015-03-06 CY CY20151100236T patent/CY1116186T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2013002740A1 (es) | Compuestos macrociclicos analogos de sangliferina, inhibidores de la ciclofilina; procedimiento de preparacion; intermediario; composicion farmaceutica; y uso en el tratamiento de infecciones virales tales como infeccion por vhc o vih, o uso como inmunosupresor o agente antiinflamatorio. | |
| DOP2022000240A (es) | Compuestos de carbamoyl piridona tricíclicos con puente y su uso farmacéutico | |
| MX372534B (es) | Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico. | |
| EP2041159B8 (en) | Macrocyclic compounds as antiviral agents | |
| UY32462A (es) | Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644 | |
| UY33183A (es) | Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento | |
| SV2005001920A (es) | " compuestos nucleosidos para el tratamiento de infecciones virales " | |
| CO6680667A2 (es) | Derivados ester de ácido borónico cíclico y sus usos terapéuticos | |
| GEP20186838B (en) | 5-phenoxy-3h-pyrimidin-4-one derivatives and their usage as hiv reverse transcriptase inhibitors | |
| CL2011002830A1 (es) | Compuestos derivados de haloalquil heteroaril benzamidas; composicion farmaceutica uso de la composicion en el tratamiento de una infeccion viral, tal como el virus de la hepatitis b y c. | |
| MX2010005292A (es) | Inhibidores de la replicacion del virus de la inmunodeficiencia humana. | |
| UA96964C2 (ru) | Соединения полициклической мочевины с антибактериальными свойствами | |
| TR201905009T4 (tr) | Polisiklik-karbamoilpiridon bileşikleri ve bunların farmasötik kullanımları. | |
| EA201390233A1 (ru) | Фармацевтические композиции | |
| AR063942A1 (es) | Compuestos de oximilo aciclico inhibidores de proteasa del virus de hepatitis c | |
| UY30544A1 (es) | Compuestos de pirrolo-piperidina y sales farmacéuticametne aceptables de los mismos, procesos de fabricacion, composiciones y aplicaciones | |
| EA201170537A1 (ru) | Ингибиторы вич-интегразы | |
| MX2012006297A (es) | Uso topico hidroxitirosol y derivados para la prevencion de la infeccion por vih. | |
| NI200700176A (es) | Compuestos peptídicos | |
| MX2012007172A (es) | Piperazinas como agentes antimalaria. | |
| MX358189B (es) | Derivados de pirimidina para el tratamiento de enfermedades bacterianas. | |
| AR125187A2 (es) | PIRIMIDINIL Y 1,3,5-TRIACINIL BENCIMIDAZOLES (ARALQUILAMINO Y HETEROARILALQUILAMINO SUSTITUIDOS EN a), SUS COMPOSICIONES FARMACÉUTICAS, Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES PROLIFERATIVAS | |
| TH174304A (th) | สารประกอบโพลีไซคลิก-คาร์บาโมอิลไพริโดน และ การใช้ทางเภสัชกรรมของสารนี้ | |
| HK1162866A (en) | Polymorphs of darunavir |